CorMedix Inc. (CRMD)

CorMedix Inc.'s stock price has experienced significant fluctuations over the past six months. In November 2025, the company reported record financial performance for Q3 2025, leading to raised full-year revenue guidance and a re-branding to CorMedix Therapeutics. In August 2025, the acquisition of Melinta Therapeutics LLC closed, diversifying CorMedix's revenue base. In June 2025, an update regarding a Large Dialysis Organization (LDO) customer led to an increase in Q2 net sales guidance. In April 2025, the company announced preliminary unaudited net revenue for Q1 2025 and increased its H1 2025 guidance. In March 2025, CorMedix reported its second full quarter of DefenCath sales, marking the first profitable commercial quarter in its history. In January 2026, CorMedix shares rose following a strong quarter report, but some analysts trimmed ratings/targets around this time.

Demand for CorMedix's products, particularly DefenCath, does not appear to be subject to negative seasonality, and the company anticipates consistent growth. Patient utilization with existing purchasing customers is forecasted to continue growing throughout 2025. The underlying demand for DefenCath is driven by structural factors such as antimicrobial resistance and the increasing prevalence of chronic diseases. The aging population also contributes to the growing demand for long-term nutritional support, including Total Parenteral Nutrition (TPN).

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases. Its primary product is DefenCath, an FDA-approved antimicrobial catheter lock solution for reducing catheter-related bloodstream infections in adult hemodialysis patients. In August 2025, CorMedix acquired Melinta Therapeutics LLC, diversifying its product portfolio. CorMedix is also exploring new indications for DefenCath, with Phase 3 studies commencing in 2025 for adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis patients.

CorMedix Inc. primarily focuses on the commercialization of DefenCath in the United States, with some sales also reported in Germany.

CorMedix's brand reputation has been bolstered by the success and unique positioning of DefenCath, the first and only FDA-approved antimicrobial catheter lock solution in the U.S. for preventing CRBSIs in hemodialysis patients. The strategic acquisition of Melinta Therapeutics in August 2025 further enhanced CorMedix's standing by diversifying its portfolio. There have been no specific events reported that negatively impacted CorMedix's brand reputation in the past year.

CorMedix Inc. has a diverse ownership structure, with institutional investors holding a significant stake of 49,766,089 shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., Marshall Wace, Llp, Deerfield Management Company, L.p. (series C), and State Street Corp. Individual insiders hold approximately 7.16% of the shares, while the general public holds around 30.3%.